Compare AOMR & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AOMR | VYGR |
|---|---|---|
| Founded | 2018 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 218.7M | 227.2M |
| IPO Year | 2019 | 2015 |
| Metric | AOMR | VYGR |
|---|---|---|
| Price | $8.27 | $3.35 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | $11.08 | ★ $16.50 |
| AVG Volume (30 Days) | 119.3K | ★ 555.6K |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | ★ 14.18% | N/A |
| EPS Growth | ★ 53.85 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,135,000.00 |
| Revenue This Year | N/A | $34.04 |
| Revenue Next Year | $1.38 | $7.92 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.96 | $2.83 |
| 52 Week High | $10.14 | $5.55 |
| Indicator | AOMR | VYGR |
|---|---|---|
| Relative Strength Index (RSI) | 46.04 | 34.70 |
| Support Level | $8.10 | $3.30 |
| Resistance Level | $8.91 | $4.29 |
| Average True Range (ATR) | 0.18 | 0.20 |
| MACD | -0.01 | -0.04 |
| Stochastic Oscillator | 57.52 | 5.52 |
Angel Oak Mortgage REIT Inc is a real estate finance company focused on acquiring and investing in the first lien non-QM loans and other mortgage-related assets in the U.S. mortgage market. Its objective is to generate attractive risk-adjusted returns for its stockholders, through cash distributions and capital appreciation across interest rates and credit cycles.
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.